Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 3/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4128743 | 0.98 | PDE4B (0.51) | PDE4DPDE4BMAPTTDP1MAPK1 | |
| SCHEMBL4118586 | 0.90 | HTT (0.53) | PDE4DMAPTTDP1MAPK1SMN1; SMN2 | |
| SCHEMBL4131305 | 0.86 | PDE4D (0.49) | PDE4DMAPTTDP1MAPK1SMN1; SMN2 | |
| SCHEMBL13957714 | 0.86 | MAPT (0.51) | PDE4DPDE4BMAPTTDP1MAPK1 | |
| SCHEMBL4255074 | 0.84 | PDE4D (0.53) | PDE4DMAPTTDP1MAPK1SMN1; SMN2 | |
| SCHEMBL4120097 | 0.84 | PDE4D (0.50) | PDE4DMAPTTDP1MAPK1SMN1; SMN2 | |
| SCHEMBL11680967 | 0.81 | PDE4D (0.52) | PDE4DMAPTTDP1MAPK1SMN1; SMN2 | |
| SCHEMBL21168982 | 0.81 | PKM (0.53) | PDE4DMAPTTDP1POLBPKM | |
| SCHEMBL4133074 | 0.79 | PDE4D (0.51) | PDE4DMAPTTDP1MAPK1SMN1; SMN2 | |
| Succinic Acid SCHEMBL28257927 | 0.79 | MAPT (0.50) | PDE4DMAPTTDP1MAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1896391-B1 | COMBRETASTATIN ANALOGS WITH TUBULIN BINDING ACTIVITY | UNIV BAYLOR (US) | 2015-08-12 | — | — | EP | disclosed |
| US-8394859-B2 | Combretastatin analogs with tubulin binding activity | BAYLOR UNIVERSITY (US) | 2013-03-12 | — | — | US | disclosed |
| US-20090075943-A1 | Combretastatin Analogs with Tubulin Binding Activity | BAYLOR UNIVERSITY | 2009-03-19 | — | — | US | disclosed |
| US-7429681-B2 | Combretastatin analogs with tubulin binding activity | BAYLOR UNIVERSITY (US) | 2008-09-30 | — | — | US | disclosed |
| US-20060293394-A1 | Combretastatin analogs with tubulin binding activity | BAYLOR UNIVERSITY | 2006-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293394-A1 | Combretastatin analogs with tubulin binding activity | TUBB, TUBB3, TUBB1 | PDE4D 1289/4885PDE4B 1242/4885MAPT 77/4885 |
| US-20090075943-A1 | Combretastatin Analogs with Tubulin Binding Activity | TUBB, TUBB3, TUBB1 | PDE4D 1289/4885PDE4B 1242/4885MAPT 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.